Aspergillus and the paediatric lung

Paediatric Respiratory Reviews

Volumn 10, Issue 4, 2009, Pages 178-185

  Hatziagorou, Elpis ^a   Walsh, Thomas J ^b   Tsanakas, John N ^a   Roilides, Emmanuel ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; Aspergilloma; Children; Invasive pulmonary aspergillosis; Neonates

Indexed keywords

ANTIFUNGAL AGENT;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; HUMAN; LUNG ASPERGILLOSIS; PATHOPHYSIOLOGY; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS;

EID: 76549135136     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2009.06.006     Document Type: Review

References (59)

1. Panagopoulou P., Filioti J., Petrikkos G., et al. Environmental surveillance of filamentous fungi in three tertiary care hospitals in Greece. J Hosp Infect 2002, 52:185-191.
2. Hope W.W., Walsh T.J., Denning D.W. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005, 43(Suppl 1):S207-238.
3. Walsh T.J., Roilides E., Cortez K., Kottilil S., Bailey J., Lyman C.A. Control, immunoregulation, and expression of innate pulmonary host defenses against Aspergillus fumigatus. Med Mycol 2005, 43(Suppl 1):S165-172.
4. Soubani A.O., Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest 2002, 121:1988-1999.
5. de Almeida M.B., Bussamra M.H., Rodrigues J.C. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006, 7:67-72.
6. Virnig C., Bush R.K. Allergic bronchopulmonary aspergillosis: a US perspective. Curr Opin Pulm Med 2007, 13:67-71.
7. Stevens D.A., Schwartz H.J., Lee J.Y., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000, 342:756-762.
8. Mastella G., Rainisio M., Harms H.K., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000, 16:464-471.
9. Geller D.E., Kaplowitz H., Light M.J., Colin A.A. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999, 116:639-646.
10. Tillie-Leblond I., Tonnel A.B. Allergic bronchopulmonary aspergillosis. Allergy 2005, 60:1004-1013.
11. Chauhan B., Santiago L., Hutcheson P.S., et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2000, 106:723-729.
12. Hartl D., Latzin P., Zissel G., Krane M., Krauss-Etschmann S., Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 173:1370-1376.
13. Miller P.W., Hamosh A., Macek M., Greenberger P.A., MacLean J., Walden S.M., Slavin R.G., Cutting G.R. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996, 59:45-51.
14. Greenberger P.A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002, 110:685-692.
15. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37(Suppl 3):S225-264.
16. Maurya V., Gugnani H.C., Sarma P.U., Madan T., Shah A. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest 2005, 127:1252-1259.
17. Crameri R. Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications. Int Arch Allergy Immunol 1998, 115:99-114.
18. Kurup V.P., Banerjee B., Hemmann S., Greenberger P.A., Blaser K., Crameri R. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy 2000, 30:988-993.
19. Wark P.A., Hensley M.J., Saltos N., et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003, 111:952-957.
20. Vlahakis N.E., Aksamit T.R. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 2001, 76:930-938.
21. Hilliard T., Edwards S., Buchdahl R., et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005, 4:215-220.
22. Casey P., Garrett J., Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002, 21:1237-1241.
23. Stevens D.A., Kan V.L., Judson M.A., et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:696-709.
24. Butz R.O., Zvetina J.R., Leininger B.J. Ten-year experience with mycetomas in patients with pulmonary tuberculosis. Chest 1985, 87:356-358.
25. Denning D.W. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001, 7(Suppl 2):25-31.
26. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000, 79:250-260.
27. Abbasi S., Shenep J.L., Hughes W.T., Flynn P.M. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999, 29:1210-1219.
28. Wald A., Leisenring W., van Burik J.A., Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175:1459-1466.
29. Hibberd P.L., Rubin R.H. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994, 19(Suppl 1):S33-40.
30. Shetty D., Giri N., Gonzalez C.E., Pizzo P.A., Walsh T.J. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1997, 16:216-221.
31. Antachopoulos C., Walsh T.J., Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr 2007, 166:1099-1117.
32. Groll A.H., Jaeger G., Allendorf A., Herrmann G., Schloesser R., von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998, 27:437-452.
33. Stergiopoulou T., Meletiadis J., Roilides E., et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007, 127:349-355.
34. Steinbach W.J. Paediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 2005, 24:358-364.
35. Zaoutis T.E., Heydon K., Chu J.H., Walsh T.J., Steinbach W.J. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Paediatrics 2006, 117:e711-716.
36. Walmsley S., Devi S., King S., Schneider R., Richardson S., Ford-Jones L. Invasive Aspergillus infections in a paediatric hospital: a ten-year review. Pediatr Infect Dis J 1993, 12:673-682.
37. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
38. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002, 21:240-248.
39. Herbrecht R., Auvrignon A., Andres E., et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001, 20:77-82.
40. Muller F.M., Trusen A., Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002, 161:563-574.
41. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., Malech H.L., Holland S.M., Ochs H., Quie P., Buckley R.H., Foster C.B., Chanock S.J., Dickler H. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79:155-169.
42. Liese J., Kloos S., Jendrossek V., et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000, 137:687-693.
43. Almyroudis N.G., Holland S.M., Segal B.H. Invasive aspergillosis in primary immunodeficiencies. Med Mycol 2005, 43(Suppl 1):S247-259.
44. Segal B.H., DeCarlo E.S., Kwon-Chung K.J., Malech H.L., Gallin J.I., Holland S.M. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998, 77:345-354.
45. Freeman A.F., Kleiner D.E., Nadiminti H., et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007, 119:1234-1240.
46. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44:373-379.
47. Thomas K.E., Owens C.M., Veys P.A., Novelli V., Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 2003, 33:453-460.
48. Taccone A., Occhi M., Garaventa A., Manfredini L., Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 1993, 23:177-180.
49. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med Mycol 2006, 44:S199-S205.
50. Steinbach W.J., Addison R.M., McLaughlin L., et al. Prospective Aspergillus galactomannan antigen testing in paediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007, 26:558-564.
51. Horvath J.A., Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100:171-178.
52. Francesconi A., Kasai M., Petraitiene R., et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006, 44:2475-2480.
53. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
54. Walsh T.J., Seibel N.L., Arndt C., et al. Amphotericin B lipid complex in paediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999, 18:702-708.
55. Walsh T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
56. Walsh T.J., Adamson P.C., Seibel N.L., et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49:4536-4545.
57. Krishna G., Sansone-Parsons A., Martinho M., Kantesaria B., Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007, 51:812-818.
58. Petraitis V., Petraitiene R., Sarafandi A.A., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834-1843.
59. Rosenberg M., Patterson R., Mintzer R., Cooper B.J., Roberts M., Harris K.E. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977, 86:405-414.